School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Ocular Therapeutix, Inc. OCUL

Healthcare · Biotechnology

$7.54last close 2026-10-09 · market cap $1.66B · delayed data

Trailing returns

1M-34.26%
3M-28.46%
6M-18.92%
1Y-36.85%
5Y-22.67%

Basis: Adjusted daily closes.

What it does

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Open OCUL in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies